A Phase 1 Study to Evaluate the Mass Balance, Metabolism, Excretion, and Pharmacokinetics of [14C]-BMS-986504 (MRTX1719) in Patients With Advanced Solid Tumors With Homozygous MTAP Deletion
Latest Information Update: 08 Nov 2024
Price :
$35 *
At a glance
- Drugs MRTX 1719 (Primary)
- Indications Solid tumours
- Focus Pharmacokinetics
- Sponsors Bristol-Myers Squibb
- 08 Nov 2024 New trial record